Hepatitis C Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography
상품코드:1707404
리서치사:Coherent Market Insights
발행일:2025년 03월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
C형 간염 치료제 세계 시장은 2025년에 98억 6,000만 달러로 추정되며, 2032년에는 132억 4,000만 달러에 달할 것으로 예상되며, 2025년부터 2032년까지 CAGR 4.3%로 성장할 것으로 예상됩니다.
보고서 범위
보고서 상세
기준 연도
2024년
2025년 시장 규모
98억 6,000만 달러
실적 데이터
2020-2024년
예측 기간
2025-2032년
예측 기간 : 2025-2032년 CAGR:
4.30%
2032년 가치 예측
132억 4,000만 달러
그림. C형 간염 치료제 시장 점유율(%), 지역별, 2025년
C형 간염은 C형 간염 바이러스에 의해 발생하는 심각한 간 손상을 유발하는 간 감염 질환입니다. 미국에서는 약 240만 명이 앓고 있습니다. 그러나 C형 간염은 증상이 거의 나타나지 않기 때문에 대부분 자각증상이 없습니다. 바이러스는 감염자의 혈액이나 체액을 통해 전파됩니다.
C형 간염의 잠복기. 최초 노출 후 발병까지의 기간입니다. 잠복기는 14-80일이며, 평균 45일입니다. 급성 C형 간염 : 바이러스가 체내에 들어온 후 6개월 동안 지속되는 단기 질환입니다. 만성 C형 간염 : C형 간염에 걸린 대부분의 사람들(85%까지)은 만성 C형 간염에 걸리면 병이 오래 지속되는 단계(6개월 이상)로 넘어가게 됩니다. 이를 만성 C형 간염 감염이라고 하며, 간암이나 간경변과 같은 심각한 건강 문제로 이어질 수 있습니다. 간경변증. 이 질병은 염증을 유발하고 시간이 지남에 따라 건강한 간세포가 흉터 조직으로 대체됩니다. 술을 마시거나 HIV에 감염되면 간경변증이 더 빨리 발생할 수 있지만, 일반적으로 간경변증은 약 20-30년 정도 걸립니다.
시장 역학:
C형 간염의 세계 유병률 증가는 예측 기간 동안 시장 성장에 도움이 될 것으로 예상됩니다. 예를 들어, 2021년 9월 18일 National Center for Biotechnology Information이 발표한 자료에 따르면, 인도의 HCV 유병률은 0.5%로 약 470만 명에서 1,090만 명이 앓고 있는 것으로 나타났습니다.
목차
제1장 조사 목적과 가정
조사 목적
가정
약어
제2장 시장 전망
보고서 설명
시장 정의와 범위
주요 요약
Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
시장 역학
성장 촉진요인
세계에서 C형 간염 만연이 증가
정부 이니셔티브 강화
성장 억제요인
부작용 증가
기회
다양한 지역에서의 제품 입수 가능성 향상
영향 분석
주요 하이라이트
규제 시나리오
제품 발매/승인
PEST 분석
PORTER의 분석
인수합병 시나리오
제4장 C형 간염 치료제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
COVID-19 역학
공급측과 수요측 분석
경제에 대한 영향
제5장 C형 간염 치료제 시장, 약물 종류별, 2020-2032년
NS3/4A 프로테아제 억제제
NS5A 억제제
NS5B 폴리메라아제 억제제
복합제
기타
제6장 C형 간염 치료제 시장, 투여 경로별, 2020-2032년
경구제
정맥내
기타
제7장 C형 간염 치료제 시장, 유통 채널별, 2020-2032년
병원 약국
소매 약국
온라인 약국
제8장 C형 간염 치료제 시장, 지역별, 2020-2032년
북미
유럽
아시아태평양
라틴아메리카
중동
아프리카
제9장 경쟁 구도
Gilead Sciences
AbbVie
Merck & Co
Bristol-Myers Squibb
Johnson & Johnson
Hoffmann-La Roche AG
Boehringer Ingelheim
Achillion Pharmaceuticals
제10장 섹션
조사 방법
출판사 소개
ksm
영문 목차
영문목차
Global Hepatitis C Drugs Market is estimated to be valued at USD 9.86 Bn in 2025 and is expected to reach USD 13.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 9.86 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
4.30%
2032 Value Projection:
USD 13.24 Bn
Figure. Hepatitis C Drugs Market Share (%), By Region 2025
Hepatitis C is a liver infection that can lead to serious liver damage. It's caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person's blood or body fluids.
Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C - up to 85% - the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.
Market Dynamics:
The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.
Hepatitis C Drugs Market Segmentation:
By Drug Class
NS3/4A Protease Inhibitors
NS5A Inhibitors
NS5B Polymerase Inhibitors
Combination Drugs
Others
By Route of Administration
Oral Drugs
Intravenous
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
Company Profiles
Gilead Sciences
AbbVie
Merck & Co
Bristol-Myers Squibb
Johnson & Johnson
Hoffmann-La Roche AG
Boehringer Ingelheim
Achillion Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Growing Prevalence of Hepatitis C Globally
Increasing Government Initiatives
Restraints
Increasing Adverse Effects
Opportunities
Increasing Product Availability in Various Regions
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
4. Hepatitis C Drugs Market- Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Hepatitis C Drugs Market, By Drug Class, 2020-2032, (US$ Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
NS3/4A Protease Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
NS5A Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
NS5B Polymerase Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Combination Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Hepatitis C Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)
Introduction
Market Share Analysis, 2025and 2032 (%)
Y-o-Y Growth Analysis, 2021- 2032
Segment Trends
Oral Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
7. Hepatitis C Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)
Introduction
Market Share Analysis, 2025and 2032 (%)
Y-o-Y Growth Analysis, 2021- 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
8. Hepatitis C Drugs Market, By Region, 2020-2032, (US$ Bn)
Introduction
Market Share Analysis, By Country, 2025and 2032 (%)
Y-o-Y Growth Analysis, For Country 2021-2032
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
U.K.
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
China
Japan
India
Australia
ASEAN
South Korea
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
